{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:39Z","timestamp":1793306019958,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia (PCP) has a significant mortality rate for non-HIV immunocompromised patients. Prevention is primarily based on combined trimethoprim and sulfamethoxazole (TMP-SMX) but guidelines on pneumocystosis prophylaxis are scattered and not consensual.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aims to describe PCP in non-HIV patients and to review case by case the prior indication of prophylaxis according to specific guidelines.<\/jats:p><jats:p>We included patients with confirmed diagnosis of PCP admitted to one university hospital from 2007 to 2020. Prior indication for pneumocystis prophylaxis was assessed according to the specific guidelines for the underlying pathology or treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 150 patients with a medical diagnosis of PCP, 78 were included. Four groups of underlying pathologies were identified: hematological pathologies (42%), autoimmune diseases (27%), organ transplantation (17%), and other pathologies at risk of PCP (14%). A small subgroup of 14 patients (18%) had received a prior prescription of pneumocystis prophylaxis but none at the time of the episode. Transfer to intensive care was necessary for 33 (42%) patients, and the mortality rate at 3\u2009months was 20%. According to international disease society guidelines, 52 patients (59%) should have been on prophylaxis at the time of the pneumocystis episode. Lowest compliance with guidelines was observed in the hematological disease group for 24 patients (72%) without prescription of indicated prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Infectious disease specialists should draw up specific prophylactic guidelines against pneumocystis to promote a better prevention of the disease and include additional criteria in their recommendations according to individual characteristics to prevent fatal cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1414092","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T04:33:55Z","timestamp":1719376435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis"],"prefix":"10.3389","volume":"11","author":[{"given":"L\u00e9o","family":"Sauvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Nourrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ruivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Le Guenno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3201\/eid0809.020096","article-title":"A new name (pneumocystis jiroveci) for pneumocystis from humans","volume":"8","author":"Stringer","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM199001183220304","article-title":"The risk of pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS cohort study group","volume":"322","author":"Phair","year":"1990","journal-title":"N Engl J Med"},{"key":"ref3","first-page":"1","article-title":"National Institutes of Health, HIV medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/1060028016650107","article-title":"Pneumocystis jirovecii pneumonia in the non-HIV-infected population","volume":"50","author":"Avino","year":"2016","journal-title":"Ann Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100400","DOI":"10.1016\/j.lanepe.2022.100400","article-title":"Evolving epidemiology of pneumocystis pneumonia: findings from a longitudinal population-based study and a retrospective multi-center study in Germany","volume":"18","author":"Kolbrink","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00277-013-1698-0","article-title":"Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"92","author":"Neumann","year":"2013","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e13587","DOI":"10.1111\/ctr.13587","article-title":"AST infectious diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation infectious diseases Community of Practice","volume":"33","author":"Fishman","year":"2019","journal-title":"Clin Transpl"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1399-3062.2011.00691.x","article-title":"Pneumocystis jirovecii pneumonia in kidney transplantation","volume":"13","author":"Goto","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12882-017-0553-2","article-title":"Renal association clinical practice guideline in post-operative care in the kidney transplant recipient","volume":"18","author":"Baker","year":"2017","journal-title":"BMC Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2147\/IDR.S199761","article-title":"Clinical characteristics, treatment outcomes, and prognostic factors of pneumocystis pneumonia in non-HIV-infected patients","volume":"12","author":"Liu","year":"2019","journal-title":"Infect Drug Resist"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1128\/JCM.00616-13","article-title":"Development and evaluation of a real-time PCR assay for detection of pneumocystis jirovecii on the fully automated BD MAX platform","volume":"51","author":"Dalpke","year":"2013","journal-title":"J Clin Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1242.e11","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12879-017-2492-8","article-title":"Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: a retrospective cohort study","volume":"17","author":"Yu","year":"2017","journal-title":"BMC Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12879-020-05082-8","article-title":"Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies","volume":"20","author":"Chadwick","year":"2020","journal-title":"BMC Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/03009742.2020.1762921","article-title":"Pneumocystis jirovecii pneumonia in patients treated for systemic autoimmune disorders: a retrospective analysis of patient characteristics and outcome","volume":"49","author":"Verhaert","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41409-018-0391-2","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?","volume":"54","author":"Redjoul","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"E362","DOI":"10.1503\/cmaj.151102","article-title":"Optimizing the language and format of guidelines to improve guideline uptake","volume":"188","author":"Gupta","year":"2016","journal-title":"CMAJ"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jclinepi.2017.08.009","article-title":"Living systematic reviews: 4. Living guideline recommendations","volume":"91","author":"Akl","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim-sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/ard.54.12.991","article-title":"Factors associated with pneumocystis carinii pneumonia in Wegener\u2019s granulomatosis","volume":"54","author":"Godeau","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","article-title":"Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid","volume":"21","author":"Chew","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia under anti-tumor necrosis factor therapy (PAT) study group. Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"CD005590","DOI":"10.1002\/14651858.CD005590.pub3","article-title":"Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2016","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14397595.2020.1812834","article-title":"The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of pneumocystis pneumonia in patients with rheumatic diseases","volume":"31","author":"Harada","year":"2020","journal-title":"Mod Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaad.2020.04.040","article-title":"Safety of trimethoprim-sulfamethoxazole for pneumocystis jirovecii pneumonia prophylaxis in patients taking methotrexate","volume":"84","author":"Havele","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e12876","DOI":"10.1111\/tid.12876","article-title":"Lymphopenia is associated with late onset pneumocystis jirovecii pneumonia in solid organ transplantation","volume":"20","author":"Werbel","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/00365540410021180","article-title":"Risk factors analysis for pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia","volume":"36","author":"Roblot","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jmii.2012.08.024","article-title":"Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals","volume":"47","author":"Li","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e13877","DOI":"10.1111\/ctr.13877","article-title":"CD4+ T cell lymphopenia predicts mortality from pneumocystis pneumonia in kidney transplant patients","volume":"34","author":"Freiwald","year":"2020","journal-title":"Clin Transpl"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.trim.2013.05.003","article-title":"Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for pneumocystis jirovecii pneumonia in kidney transplant recipients","volume":"28","author":"Sch\u00fcrmann","year":"2013","journal-title":"Transpl Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.semarthrit.2016.09.009","article-title":"Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study","volume":"46","author":"Tadros","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e1456","DOI":"10.1093\/cid\/ciaa1611","article-title":"Identification of predictive markers and outcomes of late-onset pneumocystis jirovecii pneumonia in kidney transplant recipients","volume":"73","author":"Kaminski","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e1464","DOI":"10.1093\/cid\/ciaa1619","article-title":"Targeted prophylaxis to prevent late-onset pneumocystis jirovecii pneumonia in kidney transplantation: are we there yet?","volume":"73","author":"Cervera","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e13509","DOI":"10.1111\/tid.13509","article-title":"Lifelong, universal pneumocystis jirovecii pneumonia prophylaxis: patient uptake and adherence after kidney transplant","volume":"23","author":"Peterson","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.revmed.2015.10.002","article-title":"Pneumocystosis in non-HIV-infected immunocompromised patients","volume":"37","author":"Fill\u00e2tre","year":"2016","journal-title":"Rev Med Interne"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.chest.2020.05.558","article-title":"Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases","volume":"158","author":"Ghembaza","year":"2020","journal-title":"Chest"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","article-title":"Risk factors for pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole","volume":"24","author":"Yukawa","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e13618","DOI":"10.1016\/j.heliyon.2023.e13618","article-title":"Pneumocystis pneumonia in COVID-19 patients: a comprehensive review","volume":"9","author":"Sasani","year":"2023","journal-title":"Heliyon"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"ofad043","DOI":"10.1093\/ofid\/ofad043","article-title":"Pneumocystis jirovecii infections among COVID-19 patients: a case series and literature review. Open forum","volume":"10","author":"Amstutz","year":"2023","journal-title":"Infect Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1414092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T04:33:59Z","timestamp":1719376439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1414092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":45,"alternative-id":["10.3389\/fmed.2024.1414092"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1414092","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"article-number":"1414092"}}